The global market for cancer drugs is growing rapidly, but are we any closer to beating this often fatal disease? Paul French investigates.
The pharmaceuticals industry is investing twice as much in R&D as it was a decade ago. Yet it is producing only two fifths of the new medicines it produced back...
The US government is imposing transparency rules on the relationship between physicians and pharmaceutical companies. But are the major players ready to handle this? Penny Jones reports.
Has Andrew Witty got what it takes to keep GlaxoSmithKline at the top? Nicola Boyes finds out.
Counterfeiting and fraud are significantly large risk factors when it comes to the safety of pharmaceutical products. Huw Kidwell follows the latest in developments in the pharmaceutical supply chain that...